Answers are grounded in this paper and cite their sources.
This is the most comprehensive genomic analysis of rhabdomyosarcoma to date. Despite a relatively low mutation rate, multiple genes were recurrently altered, including NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR. In addition, a majority of rhabdomyosarcoma tumors alter the receptor tyrosine kinase/RAS/PIK3CA axis, providing an opportunity for genomics-guided intervention.
No takes yet. Share an insight, caveat, or question.
Shern et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: